Head & Neck Cancers

Experts discuss the ongoing investigation of Versamune HPV plus pembrolizumab and its potential effect on outcomes in first-line HPV16-driven HNSCC.

Selumetinib led to a statistically significant and clinically meaningful improvement in ORR compared with placebo in adult patients with neurofibromatosis.

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Toripalimab has been approved in India and China’s Hong Kong Special Administrative Region for recurrent or metastatic nasopharyngeal carcinoma.

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.

The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.

Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.

Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.

The FDA has granted traditional approval to selpercatinib (Retevmo) for advanced or metastatic medullary thyroid cancer with a RET mutation.

The European Commission has approved toripalimab in indications for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.

Neoadjuvant chemotherapy improved organ preservation in nasal and paranasal sinus squamous cell carcinoma.

A CD44 and total protein level detecting oral rinse-based test showed promise in identifying disease recurrence for patients with head and neck cancer.

The FDA has granted fast track designation to APG-157 for the neoadjuvant treatment of head and neck cancer.

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.

UV1 plus pembrolizumab did not improve progression-free survival or overall survival in patients with metastatic or recurrent head and neck cancer.

The EMA’s CHMP has recommended toripalimab plus chemotherapy for metastatic nasopharyngeal carcinoma and advanced esophageal squamous cell carcinoma.

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

The ROR2-targeted ADC ozuriftamab vedotin has received FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

Frontline eftilagimod alpha plus pembrolizumab was safe and elicited responses in patients with PD-L1–negative head and neck squamous cell carcinoma.

Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.

Lori Wirth, MD, discusses the LIBRETTO-001 trial of selpercatinib for patients with advanced or metastatic RET fusion–positive thyroid cancer.

Here is your guide to the important regulatory decisions made by the FDA in June 2024.